

PORTFOLIO
NEWSLETTER

JUNE
2021

NIHR University College London Hospital Clinical Research Facility Cancer Trials



INSIDE THIS ISSUE:

- COVID-19 1
- Spotlight on Research 2
- Latest News 2
- Referral Information 3
- Open Studies 4

COVID-19 and Early Phase Cancer Trials at UCLH

During this difficult time we are trying to keep the early phase cancer trials program open to enrolment. The CRF is a geographically distinct unit to the main hospital and patients are treated in individual rooms as much as possible to minimize infection risk.

We therefore continue to welcome referrals; however due to the pressures at the front line, we are running at limited capacity and may not be able to take your patient immediately. Please liaise with the PI of the study you are considering referring to.

This newsletter provides you with details of the current ongoing cancer trials.



*Dr. Rakesh Popat, Consultant Haematologist
Cancer Lead NIHR UCLH Clinical Research Facility*

Spotlight on Research



This month we will highlight research conducted by Dr Dionysis Papadatos-Pastos.

Dionysis Papadatos-Pastos is a consultant medical oncologist and Principal Investigator specialising in the treatment of lung cancer and mesothelioma at University College London Hospitals (UCLH).

Lung cancer is the most common cause of cancer death worldwide. There have been major advances in the treatment of lung cancer however, most patients will ultimately succumb to their disease. Novel therapies are urgently needed.

The membrane type I matrix metalloproteinase (MT1-MMP) protein is involved in tissue remodelling in physiological as well as pathological processes. The presence of MT1-MMP in cancer cells has been described in Non-Small Cell Lung Cancer (NSCLC), Breast Cancer, Oesophageal Cancer and other Solid Tumours and have been linked with worse outcomes.

Consultant Medical
Oncologist

Initial attempts to therapeutically exploit matrix metalloproteinases were not successful. however, BT1718 is a novel compound that utilises the MT1-MMP axis and is designed to deliver highly active, cytotoxic payload (DM1 toxin), directly to the cancer cells with the aim to induce apoptosis, cell death and reduction of tumour size.

BT1718 in Patients With Advanced Solid Tumours:

This is a Cancer Research UK (CRUK) sponsored clinical trial and the NIHR UCL/UCLH Cancer Research Facility has joined other leading UK institutions in this National effort. The recommended dose of BT1718 has been identified in the initial dose escalation phase of the trial and we are currently running the 'expansion phase' which can be considered for patients with cancers that overexpress MT1-MMP.

BT1718 is delivered via an intravenous (IV) infusion once weekly for three consecutive weeks on a 28-day treatment cycle.

For further details on the study please visit [UCLH Find a Study Database](#) - reference [100211](#).

Latest News

UCLH CRF Fellow Presents Baseline Eye Health for DREAMM2 Trial

We are pleased to highlight our NIHR UCLH Clinical Research Facility fellow Dr. Aikaterini Kazantzi presented outcomes of the DREAMM-2 trial at two key haematology events.

The abstract 'Ocular Health of Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Baseline Data from the DREAMM-2 Trial of Belantamab Mafadotin' was accepted at the ASH Virtual Annual Meeting on 5th – 8th December 2020.

DREAMM2 phase I trial, of which CRF at UCLH was a recruiting site, investigated the use of Belantamab Mafodotin (Belamaf), an antibody drug conjugate (ADC), which binds specifically to B-cell maturation antigen (BCMA).

Dr. Kazantzi received a travel bursary by the UK Myeloma Forum for this abstract and presented the findings at the UKMF, during their Spring Day in March 2021.

We would like to congratulate Dr. Kazantzi on her achievement. The presentation can be viewed at [UK Myeloma Forum \(Spring Day 2021\)](#) and abstract can be viewed on the [ASH Virtual 2020 meeting page](#).

How to refer a patient

By Post:

NIHR UCLH Clinical Research Facility,
University College London Hospitals NHS Foundation
Trust, 4th Floor, 170 Tottenham Court Road,
London, W1T 7HA

By Telephone:

Reception: 020344 72929/72930
Reception Fax: 020344 72994

By Email*:

*When referring patients, ensure you use nhs.net emails.
Patient identifiable data *should not* be sent to/via non-
NHS email accounts.

Principal Investigators

Prof. John Bridgewater

Dr. Martin Forster

Prof. Daniel Hochhauser

Prof. Sam Janes

Dr. Mark Linch

Prof. Tim Meyer

Dr. Rowan Miller

Dr. Jenny O’Nions

Dr. Dionysis Papadatos-Pastos

Dr. Rakesh Popat

Dr. Rebecca Roylance

Dr. Beatrice Seddon

Dr. Heather Shaw

Dr. Sandra Strauss

Dr. William Townsend



Contents

As it appears in alphabetical order

Breast	Sarcoma
Gastro-Intestinal	Solid Tumours
Haematology	Urology
Hepatobiliary	

UCLH Find a Study

To find more information on UCLH CRF Early Phase Cancer Clinical Trials visit the UCLH Find a Study database:

<https://findastudy.uclh.nhs.uk/#/trial>

Using the ‘Study Name’ and/or
‘Local Project Reference’ (LRP).

NIHR UCLH Clinical Research Facility

Cancer Trials Open to Recruitment

For more information on a trial, including eligibility criteria click the hyperlinked **Local Project Reference (LRP)** ID.

Breast

Study Acronym/ Full Title	LRP	PI	Drug Class/ Tumour Target
<p>B-PRECISE-01 (MEN1611-01) Open-label, Multicentre, Phase Ib Dose-escalation Study of MEN1611-01, a P13K Inhibitor Combined with Trastuzumab ± Fulvestrant, in Subjects with PIK3CA Mutated HER2-positive Locally Recurrent Unresectable (advanced) or Metastatic Breast Cancer Progressed to Anti-HER2 Based Therapy.</p>	120910	Dr. Rebecca Roylance	<p>P13K Inhibitor</p> <p>PIK3CA Mutated HER2-positive Locally Recurrent Unresectable (advanced) or Metastatic Breast Cancer</p>

Gastro-Intestinal

Study Acronym/ Full Title	LRP	PI	Drug Class/ Tumour Target
<p>FIDES-03 (DZB-CS-202) A Phase 1b/2 study of derazantinib as monotherapy and combination therapy with paclitaxel, ramucirumab or atezolizumab in patients with HER2-negative gastric adenocarcinoma harboring FGFR genetic aberrations (FIDES-03)</p>	133317	Prof. John Bridgewater	<p>FGFR Inhibitor</p> <p>Stomach or Gastro-esophageal Adenocarcinoma harbouring FGFR2 genetic aberrations</p>

Haematology

Study Acronym/ Full Title	LRP	PI	Drug Class/ Tumour Target
<p>AML1001 A Phase 1, First in Human (FIH), Dose Escalation Study of JNJ-74856665 (dihydroorotate dehydrogenase [DHODH] Inhibitor) in Participants with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)</p>	135994	Dr. Jenny O’Nions	<p>Dihydroorotate Dehydrogenase (DHODH) Inhibitor</p> <p>Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)</p>
<p>BP41072 An Open-Label, Phase I Study To Evaluate The Safety, Pharmacokinetics And Preliminary Antitumor Activity Of Ro7227166 (A Cd19 Targeted 4-1bb Ligand) In Combination With Obinutuzumab And Incombination With Ro7082859 (Cd20-Tcb) Following A Pre-Treatment Dose Of Obinutuzumab Administered In Participants With Relapsed/ Refractory B-Cell Non-Hodgkin’s Lymphoma.</p>	129333	Dr. William Townsend	<p>Ro7227166 (CD19-directed 41BB ligand) + Obinutuzumab (anti-CD20 Monoclonal Antibody) or Glofitamab (CD3-CD20 T-Cell Bispecific Antibody)</p> <p>Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma</p>
<p>CC-220-MM-001 A Phase 1B/2A Multicenter, Open-Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose, Assess the Safety and Tolerability, Pharmacokinetics and Preliminary Efficacy of CC-220 Monotherapy and in Combination with Dexamethasone in Subjects with Relapsed and Refractory Multiple Myeloma.</p>	16/0336	Dr. Rakesh Popat	<p>Cereblon E3 Ligase Modulator</p> <p>Relapsed and Refractory Multiple Myeloma</p>

Haematology (II)

Study Acronym/ Full Title	LRP	PI	Drug Class/ Tumour Target
<p>CC-92480-MM-001 A Phase 1 Multicenter, Open-Label Study to Assess The Safety, Pharmacokinetics And Preliminary Efficacy of CC-92480 in Combination With Dexamethasone in Subjects With Relapsed And Refractory Multiple Myeloma.</p>	18/0040	Dr. Rakesh Popat	<p>Cereblon E3 Ligase Modulator Relapsed and Refractory Multiple Myeloma</p>
<p>CCS1477-02 An open-label Phase I/IIa study to evaluate the safety and efficacy of CCS1477 as monotherapy in patients with advanced haematological malignancies</p>	121140	Dr. Jenny O’Nions	<p>P300/CBP Inhibitor Advanced Haematological Malignancies</p>
<p>CL1-65487-003 Phase I / II, open label, dose escalation part (phase I) followed by non-comparative expansion part (phase II), multicentre study, evaluating safety, pharmacokinetics and efficacy of S65487, a Bcl2 inhibitor combined with azacitidine in adult patients with previously untreated acute myeloid leukemia not eligible for intensive treatment.</p>	136715	Dr. Jenny O’Nions	<p>BCL-2 Inhibitor Previously Untreated Acute Myeloid Leukaemia, not eligible for Intensive Treatment</p>
<p>CO41942 Ph1b study of bispecifics with lenalidomide in relapsed/ refractory FL.</p>	130416	Dr. William Townsend	<p>CD3-CD20 Bispecific Antibody Relapsed or Refractory Follicular Lymphoma</p>
<p>DREAMM-6 A Phase I/II, Open-label, Dose Escalation and Expansion Study to Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-Drug Conjugate GSK2857916 Administered in Combination with Lenalidomide Plus Dexamethasone (Treatment Arm A), or Bortezomib Plus Dexamethasone (Treatment Arm B) in Participants with Relapsed or Refractory Multiple Myeloma.</p>	18/0571	Dr. Rakesh Popat	<p>Humanised Monoclonal Antibody (anti-BCMA) Relapsed or Refractory Multiple Myeloma</p>
<p>EP0042-101 A Modular, Multipart, Multi-arm, Open-label, Phase I/IIa Study to Evaluate the Safety and Tolerability of EP0042 Alone and in Combination with Anti-cancer Treatments in Patients with Advanced Malignancies.</p>	134892	Dr. Jenny O’Nions	<p>FLT3 inhibitor & Aurora Kinase Inhibitor Acute Myeloid Leukaemia (AML) or Myelodysplastic Syndromes (MDS)</p>
<p>NP40126 A Phase 1b Study Evaluating Ro7082859 In Combination With Rituximab (R) Or Obinutuzumab (G) Plus Cyclophosphamide, Doxorubicin, Vincristine, And Prednisone (CHOP) In Participants With Relapsed Refractory Follicular Lymphoma (R/R FL) Or In Participants With Untreated Diffuse Large B-Cell Lymphoma</p>	17/0859	Dr. William Townsend	<p>Glofitamab (CD3-CD20 T-Cell Bispecific Antibody) Relapsed Refractory Follicular Lymphoma Or Untreated Diffuse Large B-Cell Lymphoma</p>
<p>NVG111-101 NVG111-101: An open-label, phase 1/2, first in human study investigating the safety, tolerability, pharmacokinetics and efficacy of NVG-111 in subjects with relapsed/refractory chronic lymphocytic leukaemia and mantle cell lymphoma.</p>	135715	Dr. William Townsend	<p>Receptor Tyrosine Kinase Like Orphan Like Receptor 1 (ROR1) Bispecific antibody Relapsed or Refractory Chronic Lymphocytic Leukaemia & Mantle Cell Lymphoma</p>

Haematology (III)

Study Acronym/ Full Title	LPR	PI	Drug Class/ Tumour Target
<p>Teclistamab in Relapsed or Refractory Multiple Myeloma</p> <p>A Phase 1/2b, First-in-Human, Open-Label, Dose Escalation Study of Teclistamab, a Humanised BCMA x CD3 Bispecific Antibody, in Subjects with Relapsed or Refractory Multiple Myeloma.</p>	134949	Dr. Rakesh Popat	<p>Humanised Bispecific Antibody (BCMA & CD3)</p> <p>Relapsed or Refractory Multiple Myeloma</p>

Hepatobiliary

Study Acronym/ Full Title	LPR	PI	Drug Class/ Target
<p>ADP-0033-001</p> <p>A Phase I Open Label Clinical Trial Evaluating the Safety and Anti-Tumor Activity of Autologous T Cells Expressing Enhanced TCRs Specific for Alpha Fetoprotein (AFP^{c332T}) in HLA-A2 Positive Subjects With Advanced Hepatocellular Carcinoma (HCC) or Other AFP Expressing Tumor Types.</p>	17/0093	Prof. Tim Meyer	<p>T-Cell Therapy</p> <p>Advanced Hepatocellular Carcinoma (HCC) or Other AFP Expressing Tumour Types</p>
<p>TAS-120</p> <p>A Dose Finding Phase I Study of TAS-120 in Patients with Advanced Solid Tumors With or Without Fibroblast Growth Factor/Receptor (FGF/FGFR)-Related Abnormalities Followed by a Phase 2 Study in Patients With Advanced Solid Tumors FGF/FGFR-Related Abnormalities</p>	17/0474	Prof. John Bridgewater	<p>FGFR2 Inhibitor</p> <p>Cholangiocarcinoma harbouring FGFR2 Gene Fusion</p>

Sarcoma

Study Acronym/ Full Title	LPR	PI	Drug Class/ Target
<p>Afatinib in Chordoma</p> <p>A phase 2, single arm, European multi-center trial evaluating the efficacy of afatinib as first-line or later-line treatment in advanced Chordoma.</p>	17/0146	Dr. Sandra Strauss	<p>EGFR Small Molecule Inhibitor</p> <p>Advanced Chordoma</p>

Solid Tumours

Study Acronym/ Full Title	LPR	PI	Drug Class/ Target
<p>AGI-134</p> <p>A phase I/IIa, multicentre, open label study designed to evaluate the safety and tolerability of AGI-134 as monotherapy and in combination with pembrolizumab, in unresectable metastatic solid tumours.</p>	104916	Dr. Martin Forster	<p>Anti-αGal</p> <p>Unresectable Superficial Metastatic Melanoma or Squamous Cell Cancers</p>

Solid Tumours (II)

Study Acronym/ Full Title	LPR	PI	Drug Class/ Target
BLU-667 A Phase 1 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients with Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors.	17/0783	Dr. Martin Forster	RET Inhibitor Thyroid Cancer, NSCLC, Other RET-driven Advanced Solid Tumours
BICYCLE Study: BT171/8 A Cancer Research UK Phase I/IIa trial of BT1718, (A Bicycle drug conjugate), given intravenously in patients with advanced solid tumours.	100211	Dr Dionysios Papadatos-Pastos	Bicycle Drug Conjugate Advanced Solid Tumours
D9170C00001 A Phase I/IIa, Open-Label Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Ascending Doses of AZD7648 Monotherapy or in Combination with either Cytotoxic Chemotherapies or Novel Anti-Cancer Agents in Patients with Advanced Malignancies	18/0580	Dr. Rowan Miller	DNA-PK Inhibitor Advanced Malignancies
IMC-F106C-101 A Phase 1/2 First-in-Human Study of the Safety and Efficacy of IMC-F106C as a Single Agent and in Combination with Checkpoint Inhibitors in HLA-A*02:01-Positive Participants with Advanced PRAME-Positive Cancers	130728	Dr. Heather Shaw	PRAME Immune-Mobilizing T-Cell Receptor against Cancer HLA-A*02:01-Positive Participants with Advanced PRAME-Positive Cancers
LOXO-TRK-15002 LOXO-TRK-15002: A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors.	16/0077	Dr. Martin Forster	TRK Inhibitor NTRK Fusion-Positive Tumours
MOv18 A Cancer Research UK Phase I study of MOv18 IgE, a first in class chimeric IgE antibody against folate receptor- α , in patients with advanced solid tumours.	17/0121	Dr. Rowan Miller	IgE Antibody against Folate Receptor-α Advanced Solid Tumours
MULTI-31 An open-label, Phase II, platform trial evaluating safety and efficacy of multiple BI 754091 anti-PD-1 based combination regimens in PD-(L)1 naïve and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy	123071	Dr. Martin Forster	Anti-PD-L1 Based Combination Regime PD-(L)1 naïve & PD-(L)1 pre-treated patients with advanced and/or metastatic solid tumours, had at least one line of systemic therapy.
PATRIOT A Phase I Study to assess the Tolerability, Safety and Biological Effects of a Specific Ataxia Telangiectasia and Rad3Related (ATR) Inhibitor (AZD6738) as a Single Agent and in Combination with Palliative Radiation Therapy in Patients with Solid Tumours	14/0342	Dr. Martin Forster	ATR Serine/Threonine Protein Kinase Inhibitor Solid Tumours
Starpharma CTX A phase 1/2 dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of CTX-SPL9111 (a cabazitaxel (CTX)-dendrimer conjugate) in patients with advanced solid tumours.	18/0016	Dr. Martin Forster	Drug-Dendrimer Conjugate Advanced Solid Tumours

Solid Tumours (III)

Study Acronym/ Full Title	LPR	PI	Drug Class/ Target
<p>Starpharma DTX</p> <p>A phase 1/2 dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of DTX-SPL8783 (a docetaxel (DTX)-dendrimer conjugate) as monotherapy in patients with advanced solid tumours or in combination with nintedanib in patients with non-small cell lung cancer (NSCLC).</p>	17/0585	Dr. Martin Forster	<p>Drug-Dendrimer Conjugate (Tubulin Polymerase Inhibitor)</p> <p>Advanced solid tumours Or non-small cell lung cancer (NSCLC)</p>
<p>TACTI-002</p> <p>(Two ACTive Immunotherapeutics): A multicenter, open label, phase II study in patients with previously untreated unresectable or metastatic non-small cell lung cancer (NSCLC), or recurrent PD-X refractory NSCLC or with recurrent or metastatic squamous head and neck cancer (HNSCC) receiving the soluble LAG-3 fusion protein efitilgimod alpha (IMP321) in combination with pembrolizumab (PD-1 antagonist).</p>	18/0560	Dr. Martin Forster	<p>APC Activator & Anti-PD-1 Monoclonal Antibody</p> <p>Previously untreated unresectable or metastatic non-small cell lung cancer (NSCLC), Or recurrent PD-X refractory NSCLC Or with recurrent or metastatic squamous head and neck cancer (HNSCC)</p>

Urology

Study Acronym/ Full Title	LRP	PI	Drug Class/ Target
<p>BXCL701</p> <p>A Phase 1b/2 Study of BXCL701, a Small Molecule Inhibitor of Dipeptidyl Peptidases (DPP), Administered in Combination with the Anti-Programmed Cell Death 1(PD-1) Monoclonal Antibody Pembrolizumab (PEMBRO; Keytruda®) in Patients with Small Cell Neuroendocrine Prostate Cancer (SCNC; NEPC).</p>	113103	Dr. Mark Linch	<p>Dipeptidyl Peptidases (DPP) Inhibit & Anti-PD-1 Monoclonal Antibody</p> <p>Small Cell Neuroendocrine Prostate Cancer (SCNC; NEPC)</p>
<p>FIDES-02 (DZB-CS-201)</p> <p>An open-label multi-cohort Phase 1/2 study of derazantinib and atezolizumab in patients with urothelial cancer expressing activating molecular FGFR aberrations (FIDES-02)</p>	124615	Dr. Mark Linch	<p>FGFR Inhibitor & Anti PD-L1 Monoclonal Antibody</p> <p>Advanced Urothelial Cancer expressing FGFR Genetic aberrations.</p> <p><i>Substudy 4:</i> Urothelial progression - FGFR-inhibitor resistant (>12 weeks) & previous chemo and CPI</p>
<p>PRO-MERIT</p> <p>(Prostate Cancer Messenger RNA Immunotherapy): A first-in-human, dose titration and expansion trial to evaluate safety, immunogenicity and preliminary efficacy of W_pro1 in patients with metastatic castration resistant prostate cancer and W_pro1 in combination with cemiplimab and/or goserelin acetate in patients with high-risk, localized prostate cancer.</p>	122815	Dr. Mark Linch	<p>W_pro1 mRNA Cancer Vaccine</p> <p><i>Group 1:</i> mCRPC that have exhausted conventional treatment</p> <p><i>Group 2:</i> High-risk, Localized Prostate Cancer prior to Prostatectomy</p>